Drugs / DW5121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07093697 | Mar 2024 → May 2025 | bronchitis | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW5121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07093697 ↗ |
| Route | Oral | “Participants receive DW5121, 2 tablets orally” NCT07093697 ↗ |